Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

(Reuters) - Regeneron (NASDAQ: REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...

THE TV – “Feel tired? Out of energy? Then you need Oxyoxt.” “I used to have broken bones, cancer of the thumbs and nightmares ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

True as that might be, paying with data or ads (instead of blocking ads) is usually a win-win scenario in my eyes. This won’t be everyone’s view, but as a millennial, I remember the days when ...

Nope, there’s nothing wrong with your TV—that was an ad you just saw on Amazon Prime Video. Like many of the big streaming services, Amazon Prime Video has rolled out an ad-supported tier ...

We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches, Dupixent (currently expected to reach sales of around €22 billion in 2030 7, in line with ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...